Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women

Journal of the National Cancer Institute

Volumn 100, Issue 12, 2008, Pages 898-905

  Schernhammer, Eva S ^a,b,c   Berrino, Franco ^d   Krogh, Vittorio ^d   Secreto, Giorgio ^d   Micheli, Andrea ^d   Venturelli, Elisabetta ^d   Sieri, Sabina ^d   Sempos, Christopher T ^e   Cavalleri, Adalberto ^d   Schünemann, Holger J ^e,g,h   Strano, Sabrina ^f   Muti, Paola ^g  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY AT BUFFALO   (United States)

^f Molecular Chemoprevention Unit

^g REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^h MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXYMELATONIN O SULFATE; CREATININE; HORMONE RECEPTOR; MELATONIN; TESTOSTERONE;

ADULT; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER INCIDENCE; CANCER INVASION; CANCER RISK; CASE CONTROL STUDY; CIGARETTE SMOKING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; URINALYSIS; URINE LEVEL; WOMEN'S HEALTH;

AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CREATININE; FEMALE; HUMANS; LOGISTIC MODELS; MELATONIN; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSTMENOPAUSE; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 45849147640     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn171     Document Type: Article

References (49)

1. Czeisler CA, Klerman EB. Circadian and sleep-dependent regulation of hormone release in humans. Recent Prog Horm Res. 1999;54:97-130.
2. Czeisler CA, Duffy JF, Shanahan TL, et al. Stability, precision, and near-24-hour period of the human circadian pacemaker. Science. 1999;284(5423):2177-2181.
3. Arendt J. Melatonin and the pineal gland: influence on mammalian seasonal and circadian physiology. Rev Reprod. 1998;3(1):13-22.
4. Arendt J, Bojkowski C, Franey C, Wright J, Marks V. Immunoassay of 6-hydroxymelatonin sulfate in human plasma and urine: abolition of the urinary 24-hour rhythm with atenolol. J Clin Endocrinol Metab. 1985;60(6):1166-1173.
5. Baskett JJ, Cockrem JF, Antunovich TA. Sulphatoxymelatonin excretion in older people: relationship to plasma melatonin and renal function. J Pineal Res. 1998;24(1):58-61.
6. Cook MR, Graham C, Kavet R, Stevens RG, Davis S, Kheifets L. Morning urinary assessment of nocturnal melatonin secretion in older women. J Pineal Res. 2000;28(1):41-47.
7. Lang U, Kornemark M, Aubert ML, Paunier L, Sizonenko PC. Radioimmunological determination of urinary melatonin in humans: correlation with plasma levels and typical 24-hour rhythmicity. J Clin Endocrinol Metab. 1981;53(3):645-650.
8. Leibenluft E, Feldman-Naim S, Turner EH, Schwartz PJ, Wehr TA. Salivary and plasma measures of dim light melatonin onset (DLMO) in patients with rapid cycling bipolar disorder. Biol Psychiatry. 1996;40(8):731-735.
9. Nowak R, McMillen IC, Redman J, Short RV. The correlation between serum and salivary melatonin concentrations and urinary 6-hydroxymelatonin sulphate excretion rates: two non-invasive techniques for monitoring human circadian rhythmicity. Clin Endocrinol. 1987;27(4):445-452.
10. Wetterberg L. Melatonin in humans physiological and clinical studies. J Neural Transm Suppl. 1978;13:289-310.
11. Graham C, Cook MR, Kavet R, Sastre A, Smith DK. Prediction of nocturnal plasma melatonin from morning urinary measures. J Pineal Res. 1998;24(4):230-238.
12. Schernhammer ES, Hankinson SE. Light at night: a novel risk factor for cancer in shift workers? Clin Occup Environ Med. 2003;3(2):263-278.
13. Stevens RG, Blask DE, Brainard GC, et al. Meeting report: the role of environmental lighting and circadian disruption in cancer and other diseases. Environ Health Perspect. 2007;115(9):1357-1362.
14. Cohen M, Lippman M, Chabner B. Role of pineal gland in aetiology and treatment of breast cancer. Lancet. 1978;2(8094):814-816.
15. Brzezinski A. Melatonin in humans. N Engl J Med. 1997;336(3):186-195.
16. Vijayalaxmi Thomas CR Jr, Reiter RJ, Herman TS. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol. 2002;20(10):2575- 2601.
17. Blask DE, Brainard GC, Dauchy RT, et al. Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res. 2005;65(23):11174-11184.
18. Travis RC, Allen DS, Fentiman IS, Key TJ. Melatonin and breast cancer: a prospective study. J Natl Cancer Inst. 2004;96(6):475-482.
19. Schernhammer ES, Hankinson SE. Urinary melatonin levels and breast cancer risk. J Natl Cancer Inst. 2005;97(14):1084-1087.
20. Berrino F, Muti P, Micheli A, et al. Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst. 1996;88(5):291-296.
21. Berrino F, Pisani P, Muti P. Prospective study of hormones and diet in the aetiology of breast cancer. In: Riboli E, Saracci R, eds. Diet, hormones, and cancer: methodological issues for prospective studies. Lyon, France: IARC; 1988:34-38.
22. Parkin DM, Whelan S, Ferlay J. Cancer incidence in five continents. Vol. VII. IARC Scientific Publications No. 143. Lyon, France: IARC; 1997.
23. Waterhouse J, Muir C, Shanmugaratnam K. IARC Scientific Publications. Lyon, France: IARC; 1982.
24. Barba M, Cavalleri A, Schunemann HJ, et al. Reliability of urinary 6-sulfatoxymelatonin as a biomarker in breast cancer. Int J Biol Markers. 2006;21(4):242-245.
25. Bartels H, Bohmer M, Heierli C. Serum creatinine determination without protein precipitation [in German]. Clin Chim Acta. 1972;37:193-197.
26. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44(4):1049-1060.
27. Schernhammer ES, Laden F, Speizer FE, et al. Rotating night shifts and risk of breast cancer in women participating in the Nurses' Health Study. J Natl Cancer Inst. 2001;93(20):1563-1568.
28. Davis S, Mirick DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst. 2001;93(20):1557-1562.
29. Hansen J. Increased breast cancer risk among women who work predominantly at night. Epidemiology. 2001;12(1):74-77.
30. Tamarkin L, Danforth D, Lichter A, et al. Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. Science. 1982;216(4549):1003-1005.
31. Schernhammer ES, Kroenke CH, Dowsett M, Folkerd E, Hankinson SE. Urinary 6-sulfatoxymelatonin levels and their correlations with lifestyle factors and steroid hormone levels. J Pineal Res. 2006;40(2):116-124.
32. Barr DB, Wilder LC, Caudill SP, Gonzalez AJ, Needham LL, Pirkle JL. Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. Environ Health Perspect. 2005;113(2):192-200.
33. Bartsch C, Bartsch H, Bellmann O, Lippert TH. Depression of serum melatonin in patients with primary breast cancer is not due to an increased peripheral metabolism. Cancer. 1991;67(6):1681-1684.
34. Bartsch C, Bartsch H, Fuchs U, Lippert TH, Bellmann O, Gupta D. Stage-dependent depression of melatonin in patients with primary breast cancer. Correlation with prolactin, thyroid stimulating hormone, and steroid receptors. Cancer. 1989;64(2):426-433.
35. Bartsch C, Bartsch H, Jain AK, Laumas KR, Wetterberg L. Urinary melatonin levels in human breast cancer patients. J Neural Transm. 1981;52(4):281-294.
36. Bartsch C, Bartsch H, Karenovics A, Franz H, Peiker G, Mecke D. Nocturnal urinary 6-sulphatoxymelatonin excretion is decreased in primary breast cancer patients compared to age-matched controls and shows negative correlation with tumor-size. J Pineal Res. 1997;23(2):53-58.
37. Danforth DNJ, Tamarkin L, Mulvihill JJ, Bagley CS, Lippman ME. Plasma melatonin and the hormone-dependency of human breast cancer. J Clin Oncol. 1985;3(7):941-948.
38. Falkson G, Falkson HC, Steyn ME, Rapoport BL, Meyer BJ. Plasma melatonin in patients with breast cancer. Oncology. 1990;47(5):401-405.
39. Lissoni P, Bastone A, Sala R, et al. The clinical significance of melatonin serum determination in oncological patients and its correlations with GH and PRL blood levels. Eur J Cancer Clin Oncol. 1987;23(7):949-957.
40. Lissoni P, Crispino S, Barni S, et al. Pineal gland and tumor cell kinetics: serum levels of melatonin in relation to Ki-67 labeling rate in breast cancer. Oncology. 1990;47(3):275-277.
41. Skene DJ, Bojkowski CJ, Currie JE, Wright J, Boulter PS, Arendt J. 6-sulphatoxymelatonin production in breast cancer patients. J Pineal Res. 1990;8(3):269-276.
42. Hrushesky WJ, Blask DE. Re: melatonin and breast cancer: a prospective study. J Natl Cancer Inst. 2004;96(11):888-889.
43. White IR, Brunner EJ, Barron JL. A comparison of overnight and 24 hour collection to measure urinary catecholamines. J Clin Epidemiol. 1995;48(2):263-267.
44. Janicki-Deverts D, Zilles K, Cohen S, Baum A. Can a 15-hour (overnight) urinary catecholamine measure substitute for a 24-hour measure? J Applied Biobehav Res. 2006;11(2):69-78.
45. Faber MS, Jetter A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol. 2005;97(3):125-134.
46. Hartter S, Nordmark A, Rose DM, Bertilsson L, Tybring G, Laine K. Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. Br J Clin Pharmacol. 2003;56(6):679-682.
47. Hong CC, Tang BK, Rao V, et al. Cytochrome P450 1A2 (CYP1A2) activity, mammographic density, and oxidative stress: a cross-sectional study. Breast Cancer Res. 2004;6(4):R338-R351.
48. Welsh J. Vitamin D and breast cancer: insights from animal models. Am J Clin Nutr. 2004;80(6):1721S-1724S.
49. Zhang SM. Role of vitamins in the risk, prevention, and treatment of breast cancer. Curr Opin Obstet Gynecol. 2004;16(1):19-25.